OR WAIT null SECS
Increases in efficiencies, flexibility, scalability, and sustainability are impacting adoption.
Innovation in this space depends on strategizing for GMP compliance and market access.
Despite a growing trend toward single-use bioreactors, stainless-steel retains its relevance for certain products.
This article explores a grouping strategy for therapeutic peptides incorporating theoretical and experimental methodology and results to define a practical and scientifically justified cleaning procedure.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
April 10, 2024
In back-to-back deals, Charles River will offer plasmid DNA manufacturing services for a gene therapy under development by Axovia Therapeutics and for a lead candidate being developed by Ship of Theseus.
April 08, 2024
Memel Biotech aims to offer a range of services from discovery through to formulation for preclinical through to late-stage clinical and commercial production of advanced therapies.
April 04, 2024
Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.
April 03, 2024
In a $1.8 billion transaction, Genmab will gain three clinical-stage next-generation ADC candidates with its acquisition of ProfoundBio.
NGS abbreviates drug discovery timelines.
Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.
April 02, 2024
April 01, 2024
There are considerations companies may want to consider before seeking out a service provider.